Cardon Lon 4

What Happened

• Lon Cardon, a director of Mirum Pharmaceuticals (MIRM), reported the conversion/vesting of 3,977 restricted stock units (derivative code M) into common shares on May 29, 2026. The filing shows the acquisition entry with price N/A and a matching disposition entry for 3,977 shares at $0.00. Footnotes indicate each RSU equals a contingent right to one share and that these RSUs vested on May 29, 2026.

Key Details

• Transaction date: 2026-05-29 (vesting/conversion of RSUs; code M = exercise/conversion of a derivative)
• Shares acquired: 3,977 (price reported as N/A)
• Shares disposed: 3,977 (price reported as $0.00)
• Total dollar value: Not disclosed / $0 reported for the disposition entry
• Footnotes: F1 = RSU converts to one share (or cash equivalent at issuer’s discretion); F2 = RSUs vested on May 29, 2026
• Shares owned after transaction: Not specified in the provided filing excerpt
• Timeliness: Filing marked late (“L”); late Form 4s reduce disclosure timeliness

Context

• This was not an open-market purchase or sale; it reflects the vesting/conversion of restricted stock units into shares. The simultaneous $0.00 disposition is reported but the filing does not explain whether shares were withheld for taxes, surrendered, or otherwise canceled — the footnotes only confirm the RSU vest date and conversion mechanics. For retail investors, routine RSU vesting is common compensation activity and does not by itself indicate a change in insider sentiment.